
|Articles|June 17, 2014
- Precision Diagnostics
- Volume 1
- Issue 1
Comparing Urine and Plasma Cell-Free DNA <em>BRAFV600E</em> Testing to Tissue Biopsy Mutation Testing
Author(s)Eli L. Diamond, MD
Eli L. Diamond, MD, neurologist, Memorial Sloan Kettering Cancer Center, discusses an analysis that looked at urine and plasma cell-free DNA BRAFV600E testing compared with tissue biopsy mutation testing.
Advertisement
Eli L. Diamond, MD, neurologist, Memorial Sloan Kettering Cancer Center, discusses an analysis that looked at urine and plasma cell-free DNABRAFV600Etesting compared with tissue biopsy mutation testing. This analysis was presented at the 2014 ASCO Annual Meeting.
Read about DNA in urine as a liquid biopsy for cancers and rare diseases > >
Articles in this issue
over 11 years ago
The Importance of Urine Tests for Mutation Detectionover 11 years ago
Tumor Mutational Analysis Using Urinary Cell-Free DNAAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















